Ergoteles LLC Rubius Therapeutics, Inc. Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.14 - $0.31 $8,084 - $17,901	57,747 New	57,747 $10,000
Q2 2022 Aug 12, 2022	BUY	$0.79 - $5.98 $168,754 - $1.28 Million	213,613 New	213,613 $182,000
Q1 2022 May 13, 2022	SELL	$4.25 - $10.4 $128,834 - $315,265	-30,314 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $293,439 - $537,770	30,314 New	30,314 $293,000
Q4 2020 Feb 11, 2021	SELL	$4.23 - $8.73 $56,711 - $117,043	-13,407 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.65 - $6.25 $62,342 - $83,793	13,407 New	13,407 $67,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.